PartneringPartnering
- Successful commercialisation, development and research partnerships
- Promising candidates ready for out-licensing now
- In-licensing opportunities sought for neurology, pain and oncology
Partnering is an integral part of our strategy at Vernalis. We actively in-license and out-license programmes as well as enter into research and development collaborations. We seek to in-license pre-clinical and early stage clinical programmes to complement our own development pipeline and drug discovery programmes.
Why partner with Vernalis?
Established track-record with a number of large pharmaceutical companies
Partners include Genentech, Lundbeck, Novartis, Servier and others
In-licensing opportunities
Vernalis actively seeks additional pre-clinical and early stage clinical programmes
Our key therapeutic areas include oncology, pain and neurology
Out-licensing opportunities
We have a number of promising partnership opportunities
Sharing the risks and rewards of late stage development with suitably qualified partners
V158411
A selective Chk1 (checkpoint 1) inhibitor
V158411, is the lead molecule potentially indicated for treatment of a broad range of cancers
V85546
A potent, selective MMP 12 (macrophage elastase) inhibitor
V85546 is a lead molecule with several high value potential indications
V158866
A selective FAAH (fatty acid amide hydrolase) inhibitor
V158866, is the lead molecule with potential application in pain, multiple sclerosis associated spasticity, and other neurology indications.
Latest News
Tuesday, 09 April 2013
Announcement of Results for the year ended 31 December 2012
Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2012
Product Pipeline
See at a glance what Vernalis has in development